Literature DB >> 11985793

Macrophage colony-stimulating factor (M-CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte-CSF does not.

Takao Hidaka1, Masaki Fujimura, Akitoshi Nakashima, Subaru Higuma, Naoko Yamagishi, Hiroshi Tsuda, Masatoshi Sakai, Shigeru Saito.   

Abstract

To clarify the effect of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF/CSF-1) on chemotherapy-induced infection, we estimated the effect of those CSFs on a mouse model under severe myelosuppression. First, we established an animal model in which 48.9% (22/45) of C3H/Hej mice died of sepsis related to severe myelosuppression after intraperitoneal administration of a single dose (9 mg/kg) of mitomycin C (MMC). G-CSF or M-CSF was administered to this model on various administration schedules after chemotherapy, and the effect of those CSFs on survival rates, peripheral blood granulocyte counts, expression of adhesion molecules (CD11a, CD11b, CD18) on granulocytes and granulocyte function (phagocytosis and superoxide anion production) were examined. In all G-CSF administration groups, peripheral blood granulocyte counts were increased, but improvements in expression of adhesion molecules such as CD11a and CD18, and granulocyte function were less marked and survival rates were not improved. Meanwhile, when M-CSF was administered from 1 to 7 days after chemotherapy, granulocyte and platelet counts were increased, and moreover, expression of adhesion molecules and granulocyte function were markedly improved. Furthermore, the survival rate was significantly improved to 77.8% (28/36) compared with the MMC group (P < 0.05). Positive rate of blood culture examination at 7 days after chemotherapy in the M group was 0%, and was significantly lower than that in the G group (40%) and the MMC group (40%) (P < 0.05). These results demonstrated that it is important not only to increase the granulocyte counts, but also to improve granulocyte functions for preventing infection under myelosuppression after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11985793      PMCID: PMC5927017          DOI: 10.1111/j.1349-7006.2002.tb01274.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  44 in total

1.  Demonstration of functionally distinct human polymorphonuclear leukocyte fractions by simultaneous measurement of phagocytosis and oxygen radical generation.

Authors:  K Takano; M Sasada; N Harakawa; M Nogawa; K Asagoe; K Yamamoto; M Okuma
Journal:  Int J Hematol       Date:  1997-07       Impact factor: 2.490

2.  Flow cytometric identification of murine neutrophils and monocytes.

Authors:  E Lagasse; I L Weissman
Journal:  J Immunol Methods       Date:  1996-10-16       Impact factor: 2.303

3.  Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.

Authors:  S Seropian; R Nadkarni; A P Jillella; E Salloum; B Burtness; G L Hu; D Zelterman; D L Cooper
Journal:  Bone Marrow Transplant       Date:  1999-03       Impact factor: 5.483

4.  Purification and some properties of colony-stimulating factor from normal human urine.

Authors:  K Motoyoshi; F Takaku; H Mizoguchi; Y Miura
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

5.  Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.

Authors:  K Hübel; K Hegener; R Schnell; G Mansmann; F Oberhäuser; P Staib; V Diehl; A Engert
Journal:  Ann Hematol       Date:  1999-02       Impact factor: 3.673

6.  Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy.

Authors:  A Lindemann; F Herrmann; W Oster; G Haffner; W Meyenburg; L M Souza; R Mertelsmann
Journal:  Blood       Date:  1989-12       Impact factor: 22.113

7.  Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.

Authors:  W Kern; C Aul; G Maschmeyer; R Kuse; A Kerkhoff; A Grote-Metke; H Eimermacher; U Kubica; B Wörmann; T Büchner; W Hiddemann
Journal:  Ann Hematol       Date:  1998-09       Impact factor: 3.673

8.  Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.

Authors:  C Chouaid; L Bassinet; C Fuhrman; I Monnet; B Housset
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

9.  Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT.

Authors:  Y Kawano; Y Takaue; J Mimaya; Y Horikoshi; T Watanabe; T Abe; Y Shimizu; T Matsushita; A Kikuta; A Watanabe; A Iwai; E Ito; M Endo; N Kodani; S Ohta; K Gushi; H Azuma; T Etoh; Y Okamoto; K Amano; H Hattori; H Eguchi; Y Kuroda
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

10.  In vivo effects of macrophage colony-stimulating factor on human monocyte function.

Authors:  A Khwaja; B Johnson; I E Addison; K Yong; K Ruthven; S Abramson; D C Linch
Journal:  Br J Haematol       Date:  1991-01       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.